Long-term follow-up of the STOPAGO study

Area of Science:

• Hematology
• Immunology
• Clinical Research

Background:

• Chronic immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts.
• Thrombopoietin receptor agonists (TPO-RAs) are effective in managing ITP but require long-term administration.
• Understanding the durability of response after TPO-RA discontinuation is crucial for treatment strategies.

Purpose of the Study:

• To assess the long-term sustainability of response in patients with chronic immune thrombocytopenia after discontinuing thrombopoietin receptor agonists.

Main Methods:

• An open prospective, multicenter study was conducted.
• 48 selected patients with chronic immune thrombocytopenia were enrolled.
• Patients had achieved a complete response for 1 year on TPO-RAs before enrollment.

Main Results:

• Half of the enrolled patients maintained a sustained response off treatment.
• Sustained response was observed up to 4 years after treatment discontinuation.
• This indicates a significant proportion of patients can achieve long-term remission.

Conclusions:

• A substantial proportion of patients with chronic immune thrombocytopenia may achieve sustained remission after stopping thrombopoietin receptor agonists.
• These findings suggest a potential paradigm shift in long-term ITP management.
• Further research is warranted to identify predictors of sustained response.